Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Thall

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Blood|May 1, 1996
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acidE Estey, P F Thall, K Mehta, et al.
Blood|April 9, 1999
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromeE H Estey, P F Thall, S Pierce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemiaS Faderl, P F Thall, H M Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogeneticsS M Kornblau, P F Thall, Z Estrov, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Blood|October 27, 1998
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemiaZ Estrov, P F Thall, M Talpaz, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 1995
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiformeV A Levin, M H Maor, P F Thall, et al.
Cancer|December 11, 1999
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinomaD M Gershenson, M Morris, T W Burke, et al.
British Journal of Cancer|October 9, 2008
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancerP Mathew, P F Thall, S Wen, et al.
Bone Marrow Transplantation|March 19, 2013
Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experienceM Yilmaz, R F Chemaly, X Y Han, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Blood|May 1, 1996
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acidE Estey, P F Thall, K Mehta, et al.
Blood|April 9, 1999
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromeE H Estey, P F Thall, S Pierce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemiaS Faderl, P F Thall, H M Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogeneticsS M Kornblau, P F Thall, Z Estrov, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Blood|October 27, 1998
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemiaZ Estrov, P F Thall, M Talpaz, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 1995
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiformeV A Levin, M H Maor, P F Thall, et al.
Cancer|December 11, 1999
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinomaD M Gershenson, M Morris, T W Burke, et al.
British Journal of Cancer|October 9, 2008
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancerP Mathew, P F Thall, S Wen, et al.
Bone Marrow Transplantation|March 19, 2013
Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experienceM Yilmaz, R F Chemaly, X Y Han, et al.
Pageof 6